Literature DB >> 23910645

Protein phosphatase 2A impairs IFNα-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.

V Shanker1, G Trincucci, H M Heim, H T F Duong.   

Abstract

Mammalian cells have developed several mechanisms to sense viruses and initiate adequate responses such as production of interferons. Interferons activate the antiviral response through the Jak-STAT signalling pathway. To establish a chronic infection, viruses need to counteract this barrier of defence. The hepatitis C and hepatitis B viruses are known to up-regulate the expression of protein phosphatase 2A (PP2A). In this study, we show that PP2Ac associates with Jak1/Tyk2/STAT1 and reduces Jak1/Tyk2/STAT1 phosphorylation resulting in an impairment of the IFNα-induced HCV antiviral response. Using the fully infectious HCV cell culture system (HCVcc), we demonstrate that the PP2A catalytic activity is not required to block the antiviral effect of IFNα, although it is needed to support HCVcc replication. Our data suggest an important contribution of virus-induced PP2Ac up-regulation in the establishment of a chronic infection.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV replication; STAT1; antiviral activity; interferon α; protein phosphatase 2A

Mesh:

Substances:

Year:  2013        PMID: 23910645     DOI: 10.1111/jvh.12083

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

1.  Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.

Authors:  Anupam Mukherjee; Adrian M Di Bisceglie; Ratna B Ray
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

2.  A conserved miRNA-183 cluster regulates the innate antiviral response.

Authors:  Ragunath Singaravelu; Nadine Ahmed; Curtis Quan; Prashanth Srinivasan; Christopher J Ablenas; Dominic G Roy; John Paul Pezacki
Journal:  J Biol Chem       Date:  2019-11-06       Impact factor: 5.157

Review 3.  Retroviral DNA Integration.

Authors:  Paul Lesbats; Alan N Engelman; Peter Cherepanov
Journal:  Chem Rev       Date:  2016-05-20       Impact factor: 60.622

Review 4.  Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism.

Authors:  Yuchen Nan; Chunyan Wu; Yan-Jin Zhang
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

5.  "Toll-free" pathways for production of type I interferons.

Authors:  Ling Wang; Shunbin Ning
Journal:  AIMS Allergy Immunol       Date:  2017-11-06

6.  Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome.

Authors:  Marisa Oliveira; Worachart Lert-Itthiporn; Bruno Cavadas; Verónica Fernandes; Ampaiwan Chuansumrit; Orlando Anunciação; Isabelle Casademont; Fanny Koeth; Marina Penova; Kanchana Tangnararatchakit; Chiea Chuen Khor; Richard Paul; Prida Malasit; Fumihiko Matsuda; Etienne Simon-Lorière; Prapat Suriyaphol; Luisa Pereira; Anavaj Sakuntabhai
Journal:  PLoS Negl Trop Dis       Date:  2018-02-15

7.  The Role of Zinc in Antiviral Immunity.

Authors:  Scott A Read; Stephanie Obeid; Chantelle Ahlenstiel; Golo Ahlenstiel
Journal:  Adv Nutr       Date:  2019-07-01       Impact factor: 8.701

8.  B'-protein phosphatase 2A is a functional binding partner of delta-retroviral integrase.

Authors:  Goedele N Maertens
Journal:  Nucleic Acids Res       Date:  2015-12-10       Impact factor: 16.971

Review 9.  Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists.

Authors:  Stephen B Fleming
Journal:  Vaccines (Basel)       Date:  2016-06-29

10.  HCV and flaviviruses hijack cellular mechanisms for nuclear STAT2 degradation: Up-regulation of PDLIM2 suppresses the innate immune response.

Authors:  Michael A Joyce; Karyn M Berry-Wynne; Theodore Dos Santos; William R Addison; Nicola McFarlane; Tom Hobman; D Lorne Tyrrell
Journal:  PLoS Pathog       Date:  2019-08-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.